Development and Applications of CRISPR/Cas system in cancer treatment
DOI:
https://doi.org/10.54097/9bd1t423Keywords:
CRISPR/Cas system, CAR-T therapy, UCAR-T, cancer.Abstract
Cancer has been the most severe fatal illness that has bothered people for centuries, it’s caused by the combined action of various factors such as environmental factors, genetic factors, and the immune system of the body, and their pathogenesis is complex, and the specific mechanism cannot be fully elucidated. Humans search for cure methods to heal cancer. The main treatment for malignant tumors is chemotherapy, surgery, and radiotherapy. For those who are intolerant to chemotherapy and radiotherapy or those who miss their early stage and have lost the opportunity for surgery, there is still no specific and effective therapy for patients. This leads to poor prognosis for malignant tumors of patients and a low cure rate. As people continuously explore new solutions, an experimental tool is emerging and providing hopes of curing. This tool is CRISPR/Cas system. By editing cells’ DNA that results in changes in cells’ expression, the CRISPR/CAR system may someday be able to diminish tumors without side effects. CAR-T therapy is one of the experimental therapies that altered T-cells to diminish infected cells. Currently, CAR-T cells are still encountering challenges and obstacles. After altering CAR-T cells by applying CRISPR/Cas system, the efficiency in inhibiting cancer cells increases. Applying the Cas system in developing CAR-T therapy is possible that this therapy can treat cancer patients on a large scale, have less or no side effects and increase survival rates of cancer.
Downloads
References
LIU Jiajing,WANG Wenyi,GU Jun. Research progress of CAR-T combined with immune checkpoint inhibitors or interleukin in malignant tumors[J].Medical Research and War Trauma Treatment,2023,36(02):202-208.
Siegel, R. L., Miller, K. D., Fuchs, H., & Jemal, A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 2022,72(1), 7–33.
MA Mengdan, YANG Yubin, CHEN Yanping, et al. CRISPR/Cas9 technology and its application in tumor research and treatment[J].Life Science,2021,33(11):1370-1381.
Chen Zuorui. Identification of disease-resistant molecular markers and multi-target gene editing breeding of tomato isolate[D].Huazhong Agricultural University,2020.
Makarova, K. S., et al. An updated evolutionary classification of CRISPR–Cas systems. Nature Reviews Microbiology, 2015, 13(11), 722–736.
WANG Kai, ZHOU Juhua, LI Yanmin, et al. Research progress of CRISPR/Cas9—targeted genome editing technology[J].Journal of Ludong University(Natural Science Edition),2017,33(03):218-224.
Pelea, O., et al. RNA-Responsive GRNAs for Controlling CRISPR activity: current advances, future directions, and potential applications. The CRISPR Journal, 2022, 5(5), 642–659.
ZHU Jiaohui, LUO Qun, WANG Yaofeng, et al. Homologous recombination and non-homologous terminal junction repair pathway-mediated gene editing:Cognition, application and prospect of CRISPR technology[J].Life Science,2018,30(09):1003-1009.
SUN Wenli. Molecular design and delivery method of CRISPR/Cas9 ribonucleoprotein complex with efficient homologous directional repair activity[D].Hubei University,2021.
LIU Ming'an, LI Huiyan, LI Jianming, et al. Using CRISPR/Cas9 technology to construct MLH1 gene knockout colon cancer cell Mc38 and breast cancer cell 4T1 and its microsatellite state identification[J].Journal of Jinan University(Natural Science and Medical Sciences),2022,43(02):179-190.
LI Mengyuan, JIANG Xiaomeng, SUN Qinyi, et al. Research progress of CAR-T novel combination strategy in the treatment of solid tumors[J/OL].Journal of China Pharmaceutical University:1-13[2023-08-10].
WU Qi, WANG Shaobo. Research progress of CRISPR/Cas9 technology in the treatment of CAR-T cells in the treatment of tumors[J].Basic Medicine and Clinic,2023,43(08):1313-1316.
Du Xuan. R&D status and prospect of CAR-T therapy[J].Chinese Journal of Pharmaceutical Industry,2019,50(12):1524-1529.
Dejenie, T. A., et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Taylor and Francis Online, 2022,18(6).
ZHENG Nai-hong, XU Jian-qing. Research progress of CAR-T cell immunotherapy[J].Fudan Journal (Medical Sciences),2022,49(02):295-299.
Tang, et al, A. Donor T cells for CAR T cell therapy. Biomarker Research, 2022,10(1).
REN Aihua,LIU Wan,WANG Dawei. Effect of knockout PD-L1 based on CRISPR/Cas9 technology on the sensitivity of gefitinib resistance in PC-9/T790M cells of non-small cell lung cancer[J].Journal of Jilin University(Medical Sciences),2021,47(02):292-298.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







